title: Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.
abstract: Direct delivery of aerosolized vaccines to the respiratory mucosa elicits both systemic and mucosal responses. This vaccine strategy has not been tested for Ebola virus (EBOV) or other hemorrhagic fever viruses. Here, we examined the immunogenicity and protective efficacy of an aerosolized human parainfluenza virus type 3-vectored vaccine that expresses the glycoprotein (GP) of EBOV (HPIV3/EboGP) delivered to the respiratory tract. Rhesus macaques were vaccinated with aerosolized HPIV3/EboGP, liquid HPIV3/EboGP, or an unrelated, intramuscular, Venezuelan equine encephalitis replicon vaccine expressing EBOV GP. Serum and mucosal samples from aerosolized HPIV3/EboGP recipients exhibited high EBOV-specific IgG, IgA, and neutralizing antibody titers, which exceeded or equaled titers observed in liquid recipients. The HPIV3/EboGP vaccine induced an EBOV-specific cellular response that was greatest in the lungs and yielded polyfunctional CD8+ T cells, including a subset that expressed CD103 (αE integrin), and CD4+ T helper cells that were predominately type 1. The magnitude of the CD4+ T cell response was greater in aerosol vaccinees. The HPIV3/EboGP vaccine produced a more robust cell-mediated and humoral immune response than the systemic replicon vaccine. Moreover, 1 aerosol HPIV3/EboGP dose conferred 100% protection to macaques exposed to EBOV. Aerosol vaccination represents a useful and feasible vaccination mode that can be implemented with ease in a filovirus disease outbreak situation.
authors.forename: Michelle
authors.initials: M
authors.lastname: Meyer
authors.forename: Tania
authors.initials: T
authors.lastname: Garron
authors.forename: Ndongala M
authors.initials: NM
authors.lastname: Lubaki
authors.forename: Chad E
authors.initials: CE
authors.lastname: Mire
authors.forename: Karla A
authors.initials: KA
authors.lastname: Fenton
authors.forename: Curtis
authors.initials: C
authors.lastname: Klages
authors.forename: Gene G
authors.initials: GG
authors.lastname: Olinger
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Geisbert
authors.forename: Peter L
authors.initials: PL
authors.lastname: Collins
authors.forename: Alexander
authors.initials: A
authors.lastname: Bukreyev
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D046129:Ebola Vaccines / Q000276:immunology / Q000494:pharmacology; D029043:Ebolavirus / Q000276:immunology; D004666:Encephalitis Virus, Venezuelan Equine / Q000276:immunology; D005260:Female; D019142:Hemorrhagic Fever, Ebola / Q000276:immunology* / Q000517:prevention & control*; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D008168:Lung / Q000276:immunology*; D008253:Macaca mulatta; D008297:Male; D012093:Replicon / Q000276:immunology
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D046129:Ebola Vaccines; D007070:Immunoglobulin A; D007074:Immunoglobulin G